|29th December 2020||Troy A. Ignelzi||2,131||Exercise of derivative||$9.20||$19,605.20|
|29th December 2020||Troy A. Ignelzi||5,869||Exercise of derivative||$9.20||$53,994.80|
|18th December 2020||Steven M Paul||15,000||Open or private sale||$140.00||$2,100,000.00|
|18th December 2020||Steven M Paul||15,000||Exercise of derivative||$9.30||$139,500.00|
|14th December 2020||Atul Pande||5,714||Open or private sale||$92.64||$529,344.96|
|14th December 2020||Andrew Craig Miller||12,500||Exercise of derivative||$2.92||$36,500.00|
|14th December 2020||Atul Pande||5,714||Exercise of derivative||$2.92||$16,684.88|
|10th December 2020||Andrew Craig Miller||3,571||Open or private sale||$94.82||$338,602.22|
|10th December 2020||Andrew Craig Miller||1,429||Open or private sale||$94.82||$135,497.78|
|10th December 2020||Andrew Craig Miller||1,429||Exercise of derivative||$9.20||$13,146.80|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company develops treatments for people afflicted with schizophrenia.